| Name | Title | Contact Details |
|---|
MCRA is the leading global full-service medical device, diagnostics, and biologics CRO and consulting advisory firm. MCRA delivers to its client`s industry experience, integrating its six business value creators: regulatory, clinical research, reimbursement, healthcare compliance, quality assurance, and distribution logistics to provide a dynamic, market-leading effort from innovation conception to commercialization. MCRA`s integrated application of these key value-creating initiatives provides unparalleled value for its clients. MCRA has offices in Washington, DC, Hartford, CT, New York, NY, and Tokyo, Japan and serves nearly 1,000 clients globally. Its core focus areas of therapeutic experience include orthopedics, spine, biologics, cardiovascular, diagnostic imaging, wound care, artificial intelligence, dental, anesthesia, general surgery, digital health, neurology, robotics, oncology, general and plastic surgery, urology, and in vitro diagnostic (IVD) devices and medical device cybersecurity. MCRA places particular emphasis on its expertise working with companies in all stages of development and throughout the technology life cycle by ushering technologies from the conceptual pre-clinical stage to market approval.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.
SurgiMa is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Infab Corporation is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The foundation of the business being laid in 1908 by a profound name Mr. Mohammad Fazal Elahi who started manufacturing instruments with hand and supplied it to the hospitals in the Era of Subcontinent. The company being run under the fourth generation of Mr. Mohammad Fazal Elahi with astounding experiences of more than 30 odd years in the field of surgical innovation and healthcare tools. MEDISYS is committed in providing high quality instruments. Our team is continually working on improving our methods and systems to improve the life and working of our instruments as required by our prestigious customer`s.